|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400084659 |
|
最近更新日期: Date of Last Refreshed on: |
2024-05-22 10:43:01 |
|
注册时间: Date of Registration: |
2024-05-22 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
穴位按摩干预 AD 源性 MCI 的临床研究 |
|
Public title: |
Clinical study of acupressure intervention in AD-induced MCI |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
穴位按摩干预 AD 源性 MCI 的临床研究 |
|
Scientific title: |
Clinical study of acupressure intervention in AD-induced MCI |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
徐子绚 |
研究负责人: |
刘玲 |
|
Applicant: |
Xu Zixuan |
Study leader: |
ling Liu |
|
申请注册联系人电话: Applicant telephone: |
+86 15005770157 |
研究负责人电话:
Study leader's |
+86 27 88929230 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
568623842@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
lingliu07199@aliyun.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
湖北省武汉市洪山区黄家湖西路1号湖北中医药大学 |
研究负责人通讯地址: |
湖北省武汉市武昌区花园山4号 |
|
Applicant address: |
Hubei University of Chinese Medicine, 1 Huangjiahu West Road, Hongshan District, Wuhan City, Hubei |
Study leader's address: |
No. 4 Huayuanshan, Wuchang District, Wuhan City, Hubei Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
湖北中医药大学 |
||
|
Applicant's institution: |
Hubei University of Traditional Chinese Medicine |
||
|
研究负责人所在单位: |
湖北省中医院 |
||
|
Affiliation of the Leader: |
Hubei Provincial Hospital of Traditional Chinese Medicine |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
HBZY2023-C90-02 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
湖北省中医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Hubei Province Hospital of Traditional Chinese Medicine |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-01-03 00:00:00 | ||
|
伦理委员会联系人: |
张馨 |
||
|
Contact Name of the ethic committee: |
Zhang Xin |
||
|
伦理委员会联系地址: |
湖北省武汉市武昌区花园山4号 |
||
|
Contact Address of the ethic committee: |
No. 4 Huayuanshan, Wuchang District, Wuhan City, Hubei Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 27 88920956 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
zhangxin@hbhtcm.com |
|
研究实施负责(组长)单位: |
湖北省中医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Hubei Provincial Hospital of Traditional Chinese Medicine |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
湖北省武汉市武昌区花园山4号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 4 Huayuanshan, Wuchang District, Wuhan City, Hubei Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
湖北省重点研发项目 |
||||||||||||||||||||||
|
Source(s) of funding: |
Hubei Province key research and development project |
||||||||||||||||||||||
|
研究疾病: |
阿尔茨海默病源性轻度认知功能障碍 |
||||||||||||||||||||||
|
Target disease: |
Alzheimer's disease induced mild cognitive impairment |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
1、观察穴位按摩干预 AD 源性 MCI 的临床研究及安全性。 2、为穴位干预治疗AD源轻度认知障碍提供循证医学证据。 |
||||||||||||||||||||||
|
Objectives of Study: |
1. To observe the clinical research and safety of acupressure intervention in AD-induced MCI. 2. To provide evidence-based medical evidence for acupoint intervention in the treatment of AD-derived mild cognitive impairment. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.符合 AD 源性 MCI 的诊断标准; 2.年龄 50-85 岁; 3.性别不限; 4.临床痴呆评定量表为 0.5 分; 5.总体认知功能正常:MMSE 属于正常范围; 5.日常生活能力基本正常; 7.AVLT-H 回忆延迟量表评分小于等于相应年龄组的范围下限; 8.签署知情同意书。 同时符合上述条件者,方可入选; |
||||||||||||||||||||||
|
Inclusion criteria |
1. Meet the diagnostic criteria for AD-derived MCI; 2.(2) Age 50-85 years old; 3.(3) Gender is not limited; 4.(4) The clinical dementia rating scale was 0.5 points; 5.(5) The overall cognitive function is normal: MMSE is in the normal range; 6.(6) The ability of daily living is basically normal; 7.(7) The AVLT-H recall delay scale score was less than or equal to the lower limit of the range of the corresponding age group; 8.(8) Sign informed consent. Those who meet the above conditions at the same time can be selected. |
||||||||||||||||||||||
|
排除标准: |
1.合并心、脑、肝、肾及造血系统等严重疾病者;(2)GDS-15>10分,或者有抑郁症、焦虑症等精神疾病史或家族史;(3)既往有短暂性脑缺血发作(TIA)、中风、癫痫、帕金森等病史者;(4)不能完成认知功能测定者;(5)有酗酒或精神类药物滥用史者;(6)有恶性肿瘤病史;(7)身体检查、生命体征、心电图调查中的任何其他临床显著异常或评估后有安全性风险的患者;(8)严重的视觉或听觉障碍;(9)孕妇;(10)其他原因。 符合上述任意1项者,即予排除。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Patients with serious diseases of the heart, brain, liver, kidney and hematopoietic system; 2.(2) GDS-15 > 10 points, or have a history of mental illness such as depression, anxiety or family history; 3.(3) Patients with a history of transient ischemic attack (TIA), stroke, epilepsy, Parkinson's disease; 4.(4) Those who could not complete the cognitive function measurement; 5.(5) have a history of alcohol or psychotropic substance abuse; 6.(6) Have a history of malignant tumors; 7.(7) Patients with any other clinically significant abnormality in physical examination, vital signs, ECG investigation, or safety risk after assessment; 8.(8) severe visual or hearing impairment; 9.(9) Pregnant women; 10.(10) Other reasons. Those who meet any one of the above criteria are excluded. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-01-01 00:00:00至 To 2025-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-06-01 00:00:00 至 To 2025-05-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
由统计人员运用统计软件生成随机数字表 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Random number tables were generated by statisticians using statistical software |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
对评估者设盲 |
|
Blinding: |
blinding evaluators |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
不共享 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Not to share |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case record form |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |